Big move coming,large buyers stepping up in anticipation for...

Big move coming,large buyers stepping up in anticipation for human trials,news any tick of the clock

Perth-based clinical research organisation, Linear, will assist with the first in-human study of EmtinB in healthy volunteers, with the trial seeking to assess the drug’s safety, tolerability and pharmacokinetics.

Up to 90 participants are set to be recruited, with multiple dose cohorts utilised. The study will then be used to support future Phase II trials in Alzheimer’s disease and multiple sclerosis.

“This partnership is a significant milestone for NeuroScientific and we are elated to be transitioning our R&D (research and development) program into first-in-human trials with another leading-edge, WA-based company in Linear Clinical Research,” NSB’s Managing Director, Matt Liddelow said.

“The trial is also a significant milestone for the advancement of EmtinB as a potential disease-modifying drug for a range of neurodegenerative conditions that currently lack such treatments, including Alzheimer’s disease and Multiple sclerosis.”